Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ABBVIE, LDA

NIF 510229050
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,125,089 65 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,125,089 65 contracts
A2 · Late Publication €14,991,522,363 3,288 contracts
Contract published to BASE more than 10 days after the signing date
LOW €14,991,522,363 3,288 contracts
A5 · Threshold Splitting €20,890,047 205 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €20,890,047 205 contracts
A6 · Low Competition €6,149,428 55 contracts
Only one bidder participated in a competitive procedure
MEDIUM €6,149,428 55 contracts
A9 · Price Overrun €27,187 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €27,187 1 contracts
A9 · Abnormal Price Reduction €18,573,654,243 1,503 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €18,573,654,243 1,503 contracts
C3 · Missing Mandatory Fields €10,925,430 99 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,925,430 99 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

333
€720,560,755
160
€715,003,390
76
€699,740,983
58
€672,102,082
77
€653,503,769
190
€641,393,802
66
€637,691,765
43
€633,136,345
33
€613,211,255
480
€610,200,235
168
€605,092,562
82
€602,138,110
42
€584,982,415
212
€580,824,017
37
€575,524,525
150
€567,225,194
252
€556,074,813
121
€543,555,653
32
€526,670,650
122
€512,750,093
Page 1 of 3 · 59 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 2 · 55 contracts

IMUNOMODULADORES - UPADACITINIB
PT · 11299488 · Ao abrigo de acordo-qu...
A6 · Low Competition
€160,863 2025-03-20
IMUNOMODULADORES - RISANCIZUMAB
PT · 11270452 · Ao abrigo de acordo-qu...
A6 · Low Competition
€372,514 2025-03-10
2025001630 – Aquisição de medicamentos
PT · 11263383 · Ajuste Direto Regime G...
A6 · Low Competition
€31,017 2025-03-06
Ajuste direto para aquisição de A1278 e A53284 doentes em tratamento
PT · 11262298 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€554,400 2025-02-20
CITOTÓXICOS - VENETOCLAX
PT · 11260099 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€310,260 2025-02-17
Aquisição Medicamentos Exclusivos Abbvie - Adalimumab 40 mg0.4 ml - Ano 2025
PT · 11264149 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€48,000 2025-01-24
2024006319 – Aquisição de medicamentos
PT · 11112078 · Ajuste Direto Regime G...
A6 · Low Competition
€6,530 2024-12-27
Aquisição do medicamento - Adalimumab
PT · 11203381 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€216,000 2024-12-23
Fornecimento de substância ativa: Adalimumab 80mg
PT · 11175219 · Ajuste Direto Regime G...
A5 · Threshold Splitting C3 · Missing Mandatory Fields +1
€4,800 2024-12-20
ANTIVÍRICOS HEPATITE C - ABBVIE
PT · 11094231 · Ao abrigo de acordo-qu...
A6 · Low Competition
€11,000 2024-12-18
Aquisição de UPADACITINIB 30 MG COMP LP
PT · 11094308 · Ao abrigo de acordo-qu...
A6 · Low Competition
€109,591 2024-12-18
BEAD20240553 - AQUISIÇÃO DE RMAPX- TOXINA BOTULÍNICA A
PT · 11080220 · Ao abrigo de acordo-qu...
A6 · Low Competition
€12,957 2024-12-12
BEAD20240566 - AQUISIÇÃO DE ANTIPARKINSONICOS - FOSLEVODOPA E LEVODOPA
PT · 11080140 · Ao abrigo de acordo-qu...
A6 · Low Competition
€21,508 2024-12-12
BEAD20240602 - AQUISIÇÃO DE ANTIVÍRICOS - HEPATITE C - ABBVIE
PT · 11077304 · Ao abrigo de acordo-qu...
A6 · Low Competition
€11,000 2024-12-11
Aquisição de ADALImumab 40 mg/0.4 ml Sol inj Caneta 0.4 ml SC - Abbvie
PT · 11067757 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€19,200 2024-12-05
Aquisição de ADALIMUMAB 80MG/0,8ML e 40MG/0,4ML SC INJ CANETA
PT · 11165563 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€66,720 2024-12-04
Aquisição do Medicamento Dexametasona [700 µG; IMPL INTRAVÍTREO; EMB] para a ULSCB
PT · 11064381 · Ajuste Direto Regime G...
A6 · Low Competition
€16,325 2024-12-02
J1/12/2025 - ADALIMUMAB - HUMIRA
PT · 11260750 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€8,400 2024-11-21
IMUNOMODULADORES - RISANCIZUMAB
PT · 11014864 · Ao abrigo de acordo-qu...
A6 · Low Competition
€85,964 2024-11-08
EX/3176/2024 - EPCORITAMAB 48MG/0,8ML INJ SC
PT · 11285367 · Contratação excluída II
C3 · Missing Mandatory Fields A6 · Low Competition
€91,237 2024-11-08
2024005009 – Aquisição de medicamentos
PT · 11004968 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€20,400 2024-10-23
ANTIVIRICOS HEPATITE C
PT · 10982134 · Ao abrigo de acordo-qu...
A6 · Low Competition
€44,000 2024-10-21
Ajuste direto para aquisição de A1278- Adalimumab [40 mg; caneta] (doentes em tratamento).
PT · 10983048 · Ajuste Direto Regime G...
A6 · Low Competition
€5,280 2024-10-18
Ajuste direto para aquisição de A1278- Adalimumab [40 mg; caneta] (doentes em tratamento).
PT · 10966558 · Ajuste Direto Regime G...
A6 · Low Competition
€159,840 2024-10-11
Aquisição de FOSLEVODOPA 240 MG/ML + FOSCARBIDOPA 12 MG/ML SOL INJ FR 10 ML SC (AQ2023671)
PT · 10967874 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€183,200 2024-10-03
PC 25240053 - Aquisição de Adalimumab 40MG/0.4ML
PT · 10949740 · Ajuste Direto Regime G...
A6 · Low Competition
€46,800 2024-10-03
Aquisição de UPADACITINIB 30 MG COMP LP.
PT · 10952830 · Ao abrigo de acordo-qu...
A6 · Low Competition
€117,957 2024-09-27
IMUNOMODULADORES - UPADACITINIB
PT · 10939196 · Ao abrigo de acordo-qu...
A6 · Low Competition
€17,322 2024-09-26
Fornecimento de Upadacitinib 30mg e 45mg
PT · 10943062 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€63,516 2024-09-06
Fornecimento da substância ativa: FOSLEVODOPA + FOSCARBIDOPA [240 + 12 MG/ML; SOL INJ; FRS]
PT · 10937546 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€53,807 2024-08-27
2024004591 – Aquisição de medicamentos
PT · 10840756 · Ajuste Direto Regime G...
A6 · Low Competition
€40,812 2024-07-29
Ajuste direto para aquisição de A1278- Adalimumab [40 mg; caneta] (doentes em tratamento).
PT · 10817671 · Ajuste Direto Regime G...
A6 · Low Competition
€48,720 2024-07-10
RELAXANTE MUSCULAR AÇÃO PERIFERICA - TOXINA BOTULÍNICA
PT · 10795428 · Ao abrigo de acordo-qu...
A6 · Low Competition
€10,365 2024-06-27
EAD20240095 - AQUISIÇÃO DE ANTIPARKINSONICOS - FOSLEVODOPA + FOSCARBIDOPA
PT · 10724498 · Ajuste Direto Regime G...
A6 · Low Competition
€49,536 2024-05-17
ADALIMUMAB 80 MG/0.8 ML SOL INJ CANETA 0.8 ML SC
PT · 10757807 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€12,000 2024-05-16
Aquisição de ADALImumab 20 MG/0.2 ML SOL INJ SER 0.2 ML SC e ADALImumab 40 MG/0.4 ML SOL INJ CANETA 0.4 ML SC
PT · 10936963 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€399,923 2024-05-08
UPADACITINIB 45 MG COMP LP
PT · 10983714 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€5,362 2024-04-30
BEAD20240231 - AQUISIÇÃO DE IMUNOMODULADORES - UPADACITINIB - 1º SEMESTRE
PT · 10691383 · Ao abrigo de acordo-qu...
A6 · Low Competition
€24,748 2024-04-29
ANTIPARKINSONICOS - LEVODOPA + CARBIDOPA
PT · 10687575 · Ao abrigo de acordo-qu...
A6 · Low Competition
€20,480 2024-04-26
IMUNOMODULADORES - UPADACITINIB
PT · 10680341 · Ao abrigo de acordo-qu...
A6 · Low Competition
€24,747 2024-04-22
BEAD20240211 - AQUISIÇÃO DE IMUNOMODULADORES - UPADACITINIB
PT · 10650709 · Ao abrigo de acordo-qu...
A6 · Low Competition
€28,048 2024-04-05
IMUNOMODULADORES - ADALIMUMAB
PT · 10609713 · Ao abrigo de acordo-qu...
A6 · Low Competition
€297,960 2024-03-13
UPADACITINIB 45MG+ UPADACITINIB 30MG, AO ABRIGO DO CPA 2022/55
PT · 10631999 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€100,595 2024-02-27
RELAXANTE MUSCULAR AÇÃO PERIFERICA -1º SEMESTRE
PT · 10587630 · Ao abrigo de acordo-qu...
A6 · Low Competition
€8,422 2024-02-27
adalimumab 40 mg/ 0,4 ml sol inj caneta
PT · 10581181 · Ajuste Direto Regime G...
A6 · Low Competition
€60,000 2024-02-24
IMUNOMODULADORES - RISANCIZUMAB E UPADACITINIB - 1º SEMESTRE
PT · 10577074 · Ao abrigo de acordo-qu...
A6 · Low Competition
€182,089 2024-02-22
AQUISIÇÃO DE ADALIMUMAB 40 MG/0.4 ML SOL INJ CANETA 0.4 ML SC - FARMACOVIGILÂNCIA
PT · 10937514 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€144,000 2024-02-20
AQUISIÇÃO DE MEDICAMENTOS PARA A HEPATITE C CRÓNICA AO ABRIGO DO ACORDO QUADRO 2023/494 DOS SPMS, EPE
PT · 10794422 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€49,500 2024-02-16
BEAD20240026 - AQUISIÇÃO DE CITOTOXICOS - VENETOCLAX - 1º SEMESTRE
PT · 10562579 · Ao abrigo de acordo-qu...
A6 · Low Competition
€267,873 2024-02-16
241G000278 - UPADACITINIB
PT · 10562597 · Ajuste Direto Regime G...
A6 · Low Competition
€26,448 2024-02-16
Next →
Overview
Total Value Won
€18,846,490,806
Contracts Won
4,728
Score 160085 · CRITICAL RISK
NIF
510229050
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.P. [P-93b9]
    Gerente
    since 2017-09-06
  • C.M. [P-a59e]
    Gerente
    since 2019-10-03
  • C.M. [P-a59e]
    Gerente
    since 2022-07-11
  • C.M. [P-a59e]
    Gerente
    since 2025-07-08
  • C.R. [P-5fd1]
    Gerente
    since 2020-02-19
  • F.V. [P-260a]
    Gerente
    since 2013-01-03
  • G.G. [P-b5cc]
    Gerente
    since 2023-03-31
  • G.G. [P-b5cc]
    Gerente
    since 2025-07-08
  • L.C. [P-dfea]
    Gerente
    since 2023-09-27
  • M.I. [P-bb79]
    Gerente
    since 2015-06-11
  • N.G. [P-e1e3]
    Gerente
    since 2026-04-08
  • O.M. [P-8e9a]
    Gerente
    since 2022-07-11
  • R.A. [P-6f67]
    Gerente
    since 2019-04-30
  • W.J. [P-08cb]
    Gerente
    since 2013-01-03
  • A.A. [P-0394]
    Sócio
    since 2012-04-05
  • A.A. [P-0394]
    Sócio
    since 2012-08-01
  • A.S. [P-ec2b]
    Sócio
    since 2012-04-05
  • A.S. [P-ec2b]
    Sócio
    since 2012-08-01
  • A.C. [P-59a3]
    Sócio
    since 2021-07-05
  • A.S. [P-f521]
    Sócio
    since 2021-07-05
  • A.D. [P-368d]
    Gerente
    2022-07-11 → 2023-09-27
  • C.P. [P-93b9]
    Gerente
    2019-04-30 → 2020-02-19
  • C.R. [P-5fd1]
    Gerente
    2022-07-11 → 2023-03-31
  • E.L. [P-442d]
    Gerente
    2012-04-05 → 2015-04-13
  • F.A. [P-b4fa]
    Gerente
    2012-04-05 → 2013-01-03
  • F.V. [P-260a]
    Gerente
    2015-04-13 → 2015-06-04
  • K.K. [P-2ee1]
    Gerente
    2022-07-11 → 2025-01-06
  • L.C. [P-dfea]
    Gerente
    2025-07-08 → 2026-04-08
  • M.I. [P-bb79]
    Gerente
    2019-04-30 → 2019-10-03
  • O.M. [P-8e9a]
    Gerente
    2025-07-08 → 2026-03-30
  • R.J. [P-33a8]
    Gerente
    2015-04-13 → 2017-07-24
  • T.C. [P-d023]
    Gerente
    2012-04-05 → 2013-01-03
  • W.J. [P-08cb]
    Gerente
    2015-04-13 → 2019-04-30
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned